Overview Risk of CV Events With EFV vs. EFV-free Regimens Status: Completed Trial end date: 2015-01-01 Target enrollment: Participant gender: Summary The purpose of this study is to determine whether there is an increased risk of cardiovascular events (CV) with regimens containing efavirenz (EFV) versus other regimens in patients with HIV. Details Lead Sponsor: Bristol-Myers SquibbCollaborator: Truven healthTreatments: Efavirenz